DOJ Declines Intervention in Qui Tam Lawsuit Against Corcept Therapeutics
Summary
The Department of Justice has decided not to intervene in a civil qui tam action against Corcept Therapeutics, significantly reducing the potential legal and financial risk associated with the long-running lawsuit.
Key Events
-
DOJ Declines Intervention
The U.S. Department of Justice, along with the California Department of Insurance and other plaintiff states, filed a Notice of Election to Decline Intervention in a civil qui tam action against Corcept Therapeutics.
-
Reduced Legal Risk
This decision significantly de-escalates the legal threat from the lawsuit, which was initiated by a former employee in 2017 and involved a DOJ subpoena in 2021.
-
Lawsuit Continues
Despite the DOJ's non-intervention, the former employee (Relator) has served an amended complaint, and Corcept Therapeutics intends to vigorously defend against the claims.
Analysis
The Department of Justice's decision to decline intervention in the qui tam lawsuit, which has been ongoing since 2017 and involved a subpoena in 2021, removes a major legal overhang for Corcept Therapeutics. While the former employee's lawsuit will continue, the absence of government involvement substantially reduces the potential financial penalties and reputational damage, providing a positive signal amidst recent mixed news for the company.
At the time of this filing, CORT was trading at $70.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $28.66 to $91.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.